Treatment of Transforming Growth Factor-Beta-Insensitive Mouse Renca Tumor by Transforming Growth Factor-Beta Elimination

Urology

Volumn 72, Issue 1, 2008, Pages 225-229

  Perry, Kent ^a   Wong, Larry ^a   Liu, Victoria ^a   Park, Irwin ^a   Zhang, Qiang ^a   Rejen, Varun ^a   Huang, Xuemei ^a   Smith, Norm D ^a   Jovanovic, Borko ^a   Lonning, Scott ^b   Teicher, Beverly A ^b   Lee, Chung ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANIMAL CELL; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 45849090359     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.091     Document Type: Article

References (29)

1. Massague J. The transforming growth factor β family. Ann Rev Cell Biol 6 (1990) 597-641
2. Massagué J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 1 (2000) 169-178
3. Derynck R., Akhurst R.J., and Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29 (2001) 117-129
4. Pinkas J., and Teicher B.A. TGF-β in cancer and as a therapeutic target. Biochem Pharmacol 72 (2006) 523-529
5. de Visser K.E., and Kast M.W. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13 (1999) 1188-1199
6. Matthews E., Yang T., Janulis L., et al. Down regulation of TGF-β1 production restores immunogenicity in prostate cancer cells. Br J Cancer 83 (2000) 519-525
7. Li C., Guo B., Bernabeu C., et al. Angiogenesis in breast cancer: the role of transforming growth factor β and CD105. Microsc Res Tech 52 (2001) 437-449
8. Wakefield L.M., and Roberts A.B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Gen Dev 12 (2002) 22-29
9. Derynck R., and Feng X. TGF-β receptor signaling. Biochem Biophys Acta 333 (1997) F105-F150
10. Massague J., Cheifetz S., Laiho M., et al. TGF-β. Cancer Surv 12 (1992) 81-103
11. Arteaga C.L., Coffey Jr. R.J., Dugger T.C., et al. Growth stimulation of human breast cancer cells with anti-transforming growth factor-β antibodies: evidence for negative autocrine regulation by transforming growth factor β. Cell Growth Differ 1 (1990) 367-374
12. Wu S.P., Theodorescu D., Kerbel R.S., et al. TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116 (1992) 187-196
13. Dybal E.J., Haas G.P., Maughan R.L., et al. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J Urol 148 (1992) 1331-1337
14. Hrushesky W.J., and Murphy G.P. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 9 (1997) 277-288
15. Kundu S., Kim I.Y., Zelner D., et al. Loss of expression of transforming growth factor-β type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca. J Urol 160 (1998) 1883-1888
16. Engel J.D., Kundu S.D., Yang T., et al. Introduction of transforming growth factor β type II receptor restores tumor suppressor activity in murine renal carcinoma (Renca) cells. Urology 54 (1999) 164-170
17. Zhang Q., Rubenstein J.N., Liu V.C., et al. Restoration of expression of transforming growth factor-β type II receptor in murine renal cell carcinoma (Renca) cells by 5-Aza-2′-deoxycytidine. Life Sci 76 (2005) 1159-1166
18. + T cells: eradication of autologous mouse prostate cancer. Cancer Res 65 (2005) 1761-1769
19. Ramp U., Jaquet K., Reinecke P., et al. Acquisition of TGF-β1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 76 (1997) 739-749
20. Ananth S., Knebelmann B., Gruning W., et al. Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59 (1999) 2210-2216
21. Copland J.A., Luxon B.A., Ajani L., et al. Genomic profiling identifies alterations in TGF-β signaling through loss of TGF-β receptor expression in human renal cell carcinogenesis and progression. Oncogene 22 (2003) 8053-8062
22. Dasch J., Pace D.R., Waegell W., et al. Monoclonal antibodies recognizing transforming growth factor-β: bioactivity neutralization and transforming growth factor β2 affinity purification. J Immunol 142 (1989) 1536-1541
23. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20 (1997) 165-177
24. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppresion by TGF-β inhibitors. Invest New Drugs 21 (2003) 21-32
25. Yang Y.A., Dukhanina O., Tang B., et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109 (2002) 1607-1615
26. Fakhrai H., Dorigo O., Shawler D., et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93 (1996) 2909-2914
27. Tuxhorn J.A., McAlhany S.J., Yang F., et al. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62 (2002) 6021-6025
28. Bertolino P., Deckers M., Lebrin F., et al. Transforming growth factor-β signal transduction in angiogenesis and vascular disorders. Chest 128 6 suppl (2005) 585S-590S
29. Beck C., Schreiber H., and Rowley D. Role of TGF-β in immune-evasion of cancer. Microsc Res Tech 52 (2001) 387-395